Top Page
Guorui Properties Ltd
(Frankfurt:2329)
Guorui Properties Ltd (2329) vs. iShares MSCI Hong Kong ETF (EWH)
Guorui Properties Ltd Business Overview & Revenue Model
Guorui Properties Ltd Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.71B | 2.51B | 3.90B | 9.90B | 5.77B |
| Gross Profit | 555.56M | -50.28M | 113.52M | 1.25B | 980.32M |
| EBITDA | 295.14M | -145.86M | -325.93M | 581.55M | 1.09B |
| Net Income | -1.24B | -563.97M | -912.78M | 228.33M | 98.74M |
Balance Sheet | |||||
| Total Assets | 57.20B | 56.35B | 57.39B | 61.07B | 67.52B |
| Cash, Cash Equivalents and Short-Term Investments | 158.10M | 152.22M | 189.51M | 556.87M | 1.65B |
| Total Debt | 22.79B | 22.18B | 21.25B | 20.95B | 23.52B |
| Total Liabilities | 44.83B | 42.57B | 43.01B | 45.64B | 52.41B |
| Stockholders Equity | 9.93B | 11.17B | 11.73B | 12.71B | 12.49B |
Cash Flow | |||||
| Free Cash Flow | 678.26M | 452.11M | 413.47M | 4.07B | 4.67B |
| Operating Cash Flow | 679.53M | 512.92M | 606.31M | 4.35B | 4.94B |
| Investing Cash Flow | 146.72M | 58.95M | -305.41M | 184.15M | -2.78B |
| Financing Cash Flow | -830.50M | -627.40M | -630.90M | -5.65B | -1.11B |
Guorui Properties Ltd Technical Analysis
Guorui Properties Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.24B | 3.76 | 0.67% | 6.12% | -2.39% | -129.28% | |
53 Neutral | HK$262.71M | 30.00 | -5.30% | ― | -72.42% | -1037.50% | |
48 Neutral | €382.31M | ― | -42.12% | ― | -41.41% | 44.36% | |
47 Neutral | HK$831.11M | ― | -11.65% | ― | 4.78% | -116.13% | |
40 Underperform | €227.12M | ― | ― | -15.39% | 19.69% |
Guorui Properties Ltd Corporate Events
Glory Health Industry Limited, incorporated in the Cayman Islands, has announced the appointment of three independent non-executive directors: Ms. Chen Jinrong, Mr. Deng Zhidong, and Mr. Yuan Hao. The company emphasizes the independence of these directors, confirming they have no financial or other interests in the company’s business or connections with core connected persons. This move is expected to strengthen the company’s governance and ensure compliance with relevant listing rules, potentially enhancing stakeholder confidence.
Glory Health Industry Limited, a company incorporated in the Cayman Islands, held its annual general meeting on June 30, 2025, where all proposed resolutions were passed by a majority vote. Key resolutions included the adoption of the company’s audited financial statements for 2024, the re-election of certain directors, the reappointment of WM CPA Limited as auditors, and the granting of mandates to issue and repurchase shares. The meeting’s outcomes reflect strong shareholder support for the company’s current management and strategic direction.
Glory Health Industry Limited has announced updates regarding a disclaimer of opinion issued by its auditors concerning the company’s consolidated financial statements for the year ended December 31, 2024. The disclaimer highlights material uncertainties that may impact the company’s ability to continue as a going concern. In response, the company has taken measures to address these concerns, including extending borrowings, negotiating asset sales, and applying for government approval for land returns. The management aims to complete debt restructuring and asset disposal by the second half of 2025, with regular updates to be provided every three months.
Glory Health Industry Limited, incorporated in the Cayman Islands, has announced the composition of its board of directors and the establishment of four key committees. The board includes both executive and independent non-executive directors, with Zhang Zhangsun serving as Chairman. This announcement outlines the roles and functions of each board member, highlighting the company’s governance structure and commitment to effective management.
Glory Health Industry Limited has announced the resignation of Mr. Yuan Hao from his roles as an independent non-executive director, chairman of the Internal Control Committee, and a member of the Audit Committee, effective June 10, 2025, due to work arrangements. This resignation impacts the company’s compliance with certain listing rules, as it reduces the number of independent non-executive directors and Audit Committee members below the required minimum. The company is actively seeking a suitable candidate to fill the vacancy within three months to meet regulatory requirements.
Glory Health Industry Limited has announced its upcoming annual general meeting scheduled for June 30, 2025, in Beijing. The meeting will address several key resolutions, including the adoption of audited financial statements for 2024, the re-election of directors, and the re-appointment of auditors. Additionally, the company seeks approval to allot and issue shares, which could impact its capital structure and shareholder value.